Compounds > 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone
Page last updated: 2024-08-24

2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone and Hodgkin Disease

2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone has been researched along with Hodgkin Disease in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Case, DC; Hayes, DM1
Hancock, CH; Hoffman, NW; Mondora, A; Tan, CT1

Other Studies

2 other study(ies) available for 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone and Hodgkin Disease

ArticleYear
Phase II study of aziridinylbenzoquinone in refractory lymphoma.
    Cancer treatment reports, 1983, Volume: 67, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Azirines; Benzoquinones; Bone Marrow; Cyclohexenes; Drug Evaluation; Drug Resistance; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Thrombocytopenia

1983
Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Cancer research, 1984, Volume: 44, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Central Nervous System Diseases; Child; Child, Preschool; Cyclohexenes; Drug Evaluation; Female; Hodgkin Disease; Humans; Infant; Leukemia; Male; Neoplasms

1984